IgAN Clinical Trials

34 recruitingLast updated: June 18, 2026

There are 34 actively recruiting igan clinical trials across 39 countries. Studies span Phase 2, Phase 3, Early Phase 1, Not Applicable, Phase 1. Top locations include Beijing, Beijing Municipality, China, Beijing, China, Hangzhou, Zhejiang, China. Updated daily from ClinicalTrials.gov.


IgAN Trials at a Glance

34 actively recruiting trials for igan are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Beijing, Beijing, and Hangzhou. Lead sponsors running igan studies include The Children's Hospital of Zhejiang University School of Medicine, Haisco Pharmaceutical Group Co., Ltd., and ADARx Pharmaceuticals, Inc..

Browse igan trials by phase

Treatments under study

About IgAN Clinical Trials

Looking for clinical trials for IgAN? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new IgAN trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about IgAN clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled244 locationsNCT06935357
Recruiting
Phase 2

Chinese Adults With Kidney Disease

Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled29 locationsNCT06989359
Recruiting

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)

IgA Nephropathy (IgAN)
Assistance Publique - Hôpitaux de Paris800 enrolled1 locationNCT06926244
Recruiting

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

ProlactinomaCushing DiseasePanhypopituitarism+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2,000 enrolled1 locationNCT00001595
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled17 locationsNCT06994845
Recruiting
Phase 2

A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.73 enrolled2 locationsNCT07616700
Recruiting
Phase 3

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled9 locationsNCT07390123
Recruiting
Phase 2

Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases

Focal segmental glomerulosclerosis (FSGS)IgA Nephropathy (IgAN)Minimal Change Disease (MCD)
Everest Medicines (China) Co.,Ltd.45 enrolled2 locationsNCT07614477
Recruiting
Phase 2

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled9 locationsNCT07146906
Recruiting

Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA

Familial Isolated Pituitary AdenomaAcromegalyGigantism+3 more
Barts & The London NHS Trust10,000 enrolled3 locationsNCT00461188
Recruiting
Phase 2

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Immune DysregulationPrimary Immune Regulatory DisorderChronic Granulomatous Disease+12 more
Paul Szabolcs25 enrolled1 locationNCT07284641
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Not Applicable

Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis

OsteoporosisFemale InfertilityNF-κB Ligand+2 more
Peter Humaidan100 enrolled1 locationNCT07546552
Recruiting
Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 3

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Early Phase 1

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

Huntington’s DiseaseHuntington DiseasePositron Emission Tomography+6 more
CHDI Foundation, Inc.27 enrolled1 locationNCT06634628
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499